Table 1.

BAUS guidance on the management of the prostate cancer diagnostic pathway during the COVID‐19 pandemic [1].

COVID‐19 policy recommendation 1: PSA >20 µg/mL (Category 1): Patients with a PSA >20 ng/mLwith identified metastatic disease to initiate hormone therapy.

COVID‐19 policy recommendation 2: PSA <20 µg/mL, high PSAD (Category 2): Treat as normal pathway until services restricted. Patients with PSA <20 µg/mL, but a high PSAD >0.15 µg/L/cc, with prostate volume determined on transabdominal ultrasonography or by estimated DRE, because of the presumed limited availability of MRI, should be offered a perineal prostate biopsy (potentially limited core numbers) if available in the outpatient setting. TRUS biopsy should be avoided if possible.

COVID‐19 policy recommendation 3: PSA <20 µg/mL, low PSAD (Category 3): Where the PSAD (PSA/prostate volume) is low (<0.15 µg/L/cc), all patients should be reassured, discharged and have a repeat PSA test in the primary care setting in 6 months, with re‐referral if the repeat PSA test in 6 months provides a PSAD >0.15 µg/L/cc. This PSA value should be listed in hospital correspondence.

PSAD, PSA density.